GlassScriptPhysician profile
Steven Paul Hess
NPI 1063490910
$11,219.82
in general payments reported to CMS, 2019-2025
71 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,432 · 2020: $1,415 · 2021: $2,073 · 2022: $1,631 · 2023: $1,863 · 2024: $1,246 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,669.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,657.45 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $891.68 | 2019-2025 | |
| Pfizer INC. | $622.43 | 2019-2025 | |
| Glaxosmithkline, LLC. | $528.17 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $488.97 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $440.38 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Abbott Laboratories | $308.21 | 2020-2025 | Freestyle Libre 3, Octrode |
| Amgen INC. | $305.60 | 2019-2025 | Krystexxa, Repatha, Otezla |
| Mannkind Corporation | $287.84 | 2019-2023 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $259.20 | 2019-2025 | Jardiance |
| Daiichi Sankyo INC. | $254.31 | 2019-2024 | Injectafer |
| Allergan, INC. | $238.47 | 2019-2020 | |
| Amarin Pharma, INC. | $233.19 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $210.79 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $208.92 | 2019-2023 |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $205.18 | 2020-2025 | Veozah |
| Esperion Therapeutics, INC. | $189.05 | 2020-2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $187.39 | 2021-2025 | |
| Dexcom, INC. | $155.46 | 2021-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $145.38 | 2019-2023 | Livalo |
| Novartis Pharmaceuticals Corporation | $135.93 | 2019-2024 | |
| Antares Pharma, INC. | $134.82 | 2019-2024 | Xyosted, Nocdurna, Tlando |
| Biohaven Pharmaceuticals, INC. | $129.53 | 2021 | |
| Merck Sharp & Dohme LLC | $124.02 | 2020-2024 | Capvaxive, Gardasil 9, Gardasil |
| Seqirus USA INC | $118.67 | 2022-2025 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Eisai INC. | $114.36 | 2021-2025 | |
| Medtronic, INC. | $107.04 | 2021-2024 | Corevalve Evolut R |
| Exact Sciences Corporation | $102.49 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $79.69 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $78.54 | 2019-2022 | |
| Abiomed | $71.39 | 2024-2025 | Impella |
| Biohaven Pharmaceutical Holding Company LTD. | $70.00 | 2022 | |
| Genentech USA, INC. | $61.57 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $56.23 | 2022-2023 | Gvoke Hypopen |
| Insulet Corporation | $53.53 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $51.26 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $51.18 | 2019-2024 | Spravato |
| Sumitomo Pharma America, INC. | $50.28 | 2024-2025 | Gemtesa |
| Shield Therapeutics INC | $48.16 | 2022-2025 | |
| Vbi Vaccine (Delaware) INC. | $44.39 | 2022-2023 | Prehevbrio |
| Clarus Therapeutics INC. | $44.17 | 2021 | |
| Halozyme INC | $39.85 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.25 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $36.47 | 2023-2024 | Voquezna |
| Verona Pharma, INC. | $33.88 | 2025 | Ohtuvayre |
| Teva Pharmaceuticals USA, INC. | $33.85 | 2022 | |
| Inari Medical, INC. | $33.52 | 2023-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Idorsia Pharmaceuticals US INC | $30.78 | 2023 | Quviviq |
| Corcept Therapeutics | $29.58 | 2025 | Korlym |
| Zealand Pharma US, INC. | $29.37 | 2020 | |
| Arbor Pharmaceuticals, INC. | $29.27 | 2020 | |
| Currax Pharmaceuticals LLC | $27.69 | 2020-2022 | |
| Ironwood Pharmaceuticals, INC | $23.85 | 2020 | |
| Stryker Corporation | $22.17 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Supernus Pharmaceuticals, INC. | $21.86 | 2022 | Xyosted |
| Nabriva Therapeutics, Plc | $19.38 | 2021 | |
| Axsome Therapeutics, INC. | $19.07 | 2025 | Symbravo |
| Tonix Medicines, INC. | $18.28 | 2025 | Tonmya |
| Edwards Lifesciences Corporation | $17.75 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| E.R. Squibb & Sons, L.L.C. | $15.99 | 2019 | |
| Philips North America LLC | $15.56 | 2020 | |
| Vivus LLC | $15.36 | 2021 | |
| Inspire Medical Systems, INC. | $15.13 | 2025 | Inspire |
| Sanofi Pasteur INC. | $14.69 | 2022 | |
| Hikma Pharmaceuticals USA | $14.52 | 2023 | Ryaltris |
| Corium, LLC | $14.26 | 2022 | |
| Adlon Therapeutics L.P. | $14.11 | 2019 | |
| Upsher-Smith Laboratories LLC | $12.85 | 2019 | |
| Acerus Pharmaceuticals Corporation | $12.32 | 2022 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Vistapharm, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Hess listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.